Present and new treatment strategies in the management of glaucoma

Open Ophthalmology Journal

Volumn 9, Issue 1, 2015, Pages 89-100

  Kolko, M ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

Glaucoma; Intraocular pressure lowering drugs; Neuroprotection; Neuroregeneration; Treatment strategies

Indexed keywords

ADENOSINE; ADRENERGIC RECEPTOR STIMULATING AGENT; AMYLOID BETA PROTEIN; ANGIOTENSIN II; ARACHIDONIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CILIARY NEUROTROPHIC FACTOR; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; FORSKOLIN; GHRELIN; HEAT SHOCK PROTEIN; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; PHOSPHOLIPASE A2; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; RHO KINASE; SEROTONIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ANEMIA; ANOREXIA; AQUEOUS HUMOR FORMATION; ARTICLE; BLINDNESS; BLURRED VISION; CELL REGENERATION; DEPRESSION; DROWSINESS; EXCITOTOXICITY; EYE DISCOMFORT; EYE IRRITATION; EYE REDNESS; FATIGUE; GLAUCOMA; GLIA CELL; HEADACHE; HUMAN; IMMUNE RESPONSE; IMPOTENCE; INFLAMMATION; INTRAOCULAR PRESSURE; LASSITUDE; METABOLIC ACIDOSIS; NEPHROLITHIASIS; NERVE FIBER DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FOLDING; RETINA GANGLION CELL; STEM CELL TRANSPLANTATION; TRABECULAR MESHWORK; VISION; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 84941337501     PISSN: None     EISSN: 18743641     Source Type: Journal    
DOI: 10.2174/1874364101509010089     Document Type: Article

References (168)

1. Tham Y-C, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11): 2081-90
2. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012; 119(5): 979-86
3. Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120(6): 714-20 discussion 829-30
4. Pinazo-Durán MD, Zanón-Moreno V, García-Medina JJ, Gallego- Pinazo R. Evaluation of presumptive biomarkers of oxidative stress, immune response and apoptosis in primary open-angle glaucoma. Curr Opin Pharmacol 2013; 13(1): 98-107
5. Weinreb RN. Glaucoma neuroprotection: What is it? why is it needed? Can J Ophthalmol 2007; 42(3): 396-8
6. Wierzbowska J, Robaszkiewicz J, Figurska M, Stankiewicz A. Future possibilities in glaucoma therapy. Med Sci Monit 2010; 16(11): RA252-9
7. Heijl A., Bengtsson B., Hyman L., Leske MC., Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology 2009; 116(12): 2271-6
8. Quigley HA. Glaucoma. Lancet 2011; 377(9774): 1367-77
9. Metoki T, Ohguro H, Ohguro I, Mamiya K, Ito T, Nakazawa M. Study of effects of antiglaucoma eye drops on N-methyl-D-aspartate-induced retinal damage. Jpn J Ophthalmol 2005; 49(6): 453-61
10. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 2001; 42(3): 688-94
11. Mizuno K, Koide T, Saito N, et al. Topical nipradilol: effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 2002; 43(10): 3243-50
12. Inoue K, Okugawa K, Kato S, et al. Ocular factors relevant to antiglaucomatous eyedroprelated keratoepitheliopathy. J Glaucoma 2003; 12(6): 480-5
13. Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol 1984; 97(1): 86-92
14. Lichter PR, Newman LP, Wheeler NC, Beall OV. Patient tolerance to carbonic anhydrase inhibitors. Am J Ophthalmol 1978; 85(4): 495-502
15. Konowal A, Morrison JC, Brown SV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999; 127(4): 403-6
16. Inoue K, Wakakura M, Inoue J, Matsuo H, Hara T, Tomita G. Adverse reaction after use of latanoprost in Japanese glaucoma patients. Nippon Ganka Gakkai Zasshi 2006; 110(8): 581-7
17. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103(11): 1916-24
18. Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond) 2012; 26(11): 1465-72
19. Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999; 127(5): 602-4
20. Butler P, Mannschreck M, Lin S, Hwang I, Alvarado J. Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995; 113(3): 293-6
21. Krupin T., Liebmann JM., Greenfield DS., Ritch R., Gardiner S., Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am J Ophthalmol 2011; 151(4): 671-81
22. Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology 1982; 89(1): 76-80
23. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 2002; 43(3): 716-22
24. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002; 47(Suppl 1): S53-64
25. Fukata Y, Amano M, Kaibuchi K. Rho-rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of nonmuscle cells. Trends Pharmacol Sci 2001; 22(1): 32-9
26. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001; 42(1): 137-44
27. Rao PV, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp Eye Res 2005; 80(2): 197-206
28. Tian B, Geiger B, Epstein DL, Kaufman PL. Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest Ophthalmol Vis Sci 2000; 41(3): 619-23
29. Tian B, Brumback LC, Kaufman PL. ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey eye. Exp Eye Res 2000; 71(6): 551-66
30. Kaufman PL. Pharmacologic trabeculocanalotomy. Facilitating aqueous outflow by assaulting the meshwork cytoskeleton, junctional complexes, and extracellular matrix. Arch Ophthalmol 1992; 110(1): 34-6
31. Beidoe G, Mousa SA. Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol 2012; 6: 1699-707
32. Lee AJ, Goldberg I. Emerging drugs for ocular hypertension. Expert Opin Emerg Drugs 2011; 16(1): 137-61
33. Muñoz-Negrete FJ, Pérez-López M, Kim HRW, Rebolleda G. New developments in glaucoma medical treatment. Arch Soc Esp Oftalmol 2009; 84(10): 491-500
34. Fukiage C, Mizutani K, Kawamoto Y, Azuma M, Shearer TR. Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular meshwork and ciliary muscle contraction. Biochem Biophys Res Commun 2001; 288(2): 296-300
35. Nakajima E, Nakajima T, Minagawa Y, Shearer TR, Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005; 94(4): 701-8
36. Vohra V, Chawla H, Malvika G. Rock inhibitors: future of antiglaucoma medication. Ophthalmol Res 2014; 2(6): 361-7
37. Chen J, Runyan SA, Robinson MR. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol 2011; 5: 667-77
38. Tanihara H., Inatani M., Honjo M., Tokushige H., Azuma J., Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol 2008; 126(3): 309-15
39. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007; 48(7): 3216-22
40. Rao VP., Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007; 21(3): 167-77
41. Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with normal tension glaucoma: clinical and fundamental studies. Surv Ophthalmol 1995; 39(Suppl 1): S49-56
42. Choritz L., Machert M., Thieme H. Correlation of endothelin-1 concentration in aqueous humor with intraocular pressure in primary open angle and pseudoexfoliation glaucoma. Invest Ophthalmol Vis Sci 2012; 53(11): 7336-42
43. Källberg ME, Brooks DE, Gelatt KN, Garcia-Sanchez GA, Szabo NJ, Lambrou GN. Endothelin-1, nitric oxide, and glutamate in the normal and glaucomatous dog eye. Vet Ophthalmol 2007; 10(Suppl 1): 46-52
44. Renieri G, Choritz L, Rosenthal R, Meissner S, Pfeiffer N, Thieme H. Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork. Graefes Arch Clin Exp Ophthalmol 2008; 246(8): 1107-15
45. Cellini M, Strobbe E, Gizzi C, Balducci N, Toschi PG, Campos EC. Endothelin-1 plasma levels and vascular endothelial dysfunction in primary open angle glaucoma. Life Sci 2012; 91(13-14): 699-702
46. Buckley C, Hadoke PWF, Henry E, O'Brien C. Systemic vascular endothelial cell dysfunction in normal pressure glaucoma. Br J Ophthal 2002; 86(2): 227-32
47. Minton AZ, Phatak NR, Stankowska DL, et al. Endothelin B receptors contribute to retinal ganglion cell loss in a rat model of glaucoma. PLoS ONE 2012; 7(8): e43199
48. Cherecheanu AP, Garhofer G, Schmidl D, Werkmeister R, Schmetterer L. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol 2013; 13(1): 36-42
49. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004; 62(6): 455-9
50. Vohra R, Tsai JC, Kolko M. The role of inflammation in the pathogenesis of glaucoma. Surv Ophthalmol 2013; 58(4): 311-20
51. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci 1995; 36(9): 1765-73
52. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res 2000; 19(3): 271-95
53. Min SH, Lee T-I, Chung YS, Kim HK. Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. Korean J Ophthalmol 2006; 20(3): 162-5
54. Trivedi RH, Nutaitis M, Vroman D, Crosson CE. Influence of race and age on aqueous humor levels of transforming growth factor-beta 2 in glaucomatous and nonglaucomatous eyes. J Ocul Pharmacol Ther 2011; 27(5): 477-80
55. Prendes MA, Harris A, Wirostko BM, Gerber AL, Siesky B. The role of transforming growth factor β in glaucoma and the therapeutic implications. Br J Ophthalmol 2013; 97(6): 680-6
56. Gottanka J, Chan D, Eichhorn M, Lütjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci 2004; 45(1): 153-8
57. Walshe TE, Leach LL, D'Amore PA. TGF-β signaling is required for maintenance of retinal ganglion cell differentiation and survival. Neuroscience 2011; 189: 123-31
58. Ueda K, Nakahara T, Mori A, Sakamoto K, Ishii K. Protective effects of TGF-β inhibitors in a rat model of NMDA-induced retinal degeneration. Eur J Pharmacol 2013; 699(1-3): 188-93
59. Tao Y-J, Gao D-W, Yu M. TGF-β(1) in retinal ganglion cells in rats with chronic ocular hypertension: its expression and anti-apoptotic effect. Int J Ophthalmol 2011; 4(4): 396-401
60. Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4(1): 4
61. O'Donovan HC., Hickey F., Brazil DP., et al. Connective tissue growth factor antagonizes transforming growth factor-β1/Smad signalling in renal mesangial cells. Biochem J 2012; 441(1): 499-510
62. Faherty N, Curran SP, O'Donovan H, et al. CCN2/CTGF increases expression of miR-302 microRNAs, which target the TGFβ type II receptor with implications for nephropathic cell phenotypes. J Cell Sci 2012; 125(Pt 23): 5621-9
63. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res 2010; 316(8): 1284-8
64. Civan MM, Macknight ADC. The ins and outs of aqueous humour secretion. Exp Eye Res 2004; 78(3): 625-31
65. Comes N, Buie LK, Borrás T. Evidence for a role of angiopoietinlike 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma. Genes Cells 2011; 16(2): 243-59
66. Rocha-Sousa A, Rodrigues-Araújo J, Gouveia P, et al. New therapeutic targets for intraocular pressure lowering. ISRN Ophthalmol 2013; 2013: 261386
67. Vaajanen A, Vapaatalo H. Local ocular renin-angiotensin systema target for glaucoma therapy? Basic Clin Pharmacol Toxicol 2011; 109(4): 217-24
68. Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol 2008; 6(4): 293-310
69. Rocha-Sousa A, Pereira-Silva P, Tavares-Silva M, et al. Identification of the ghrelin-GHSR 1 system and its influence in the modulation of induced ocular hypertension in rabbit and rat eyes. Peptides 2014; 57: 59-66
70. Pinar-Sueiro S, Rodríguez-Puertas R, Vecino E. Cannabinoid applications in glaucoma. Arch Soc Esp Oftalmol 2011; 86(1): 16-23
71. Metzger H, Lindner E. The positive inotropic-acting forskolin, a potent adenylate cyclase activator. Arzneimittelforschung 1981; 31(8): 1248-50
72. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Arch Ophthalmol 1980; 98(12): 2163-71
73. Shiose Y, Kitazawa Y, Tsukahara S, et al. Epidemiology of glaucoma in Japan--a nationwide glaucoma survey. Jpn J Ophthalmol 1991; 35(2): 133-55
74. Furuya T, Pan Z, Kashiwagi K. Role of retinal glial cell glutamate transporters in retinal ganglion cell survival following stimulation of NMDA receptor. Curr Eye Res 2012; 37(3): 170-8
75. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330(9): 613-22
76. Salt TE, Cordeiro MF. Glutamate excitotoxicity in glaucoma: throwing the baby out with the bathwater? Eye (Lond) 2006; 20(6): 730-32
77. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE. Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res 1997; 58(8): 864-7
78. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114(3): 299-305
79. Johnson EC, Deppmeier LM, Wentzien SK, Hsu I, Morrison JC. Chronology of optic nerve head and retinal responses to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2000; 41(2): 431-42
80. Greenfield DS, Girkin C, Kwon YH. Memantine and progressive glaucoma. J Glaucoma 2005; 14(1): 84-6
81. Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures. Invest Ophthalmol Vis Sci 2004; 45(8): 2625-39
82. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002; 958(1): 210-21
83. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009; 87(4): 450-4
84. Martin KRG., Levkovitch-Verbin H., Valenta D., Baumrind L., Pease ME., Quigley HA. Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest Ophthalmol Vis Sci 2002; 43(7): 2236-43
85. Sullivan RKP, WoldeMussie E, Macnab L, Ruiz G, Pow DV. Evoked expression of the glutamate transporter GLT-1c in retinal ganglion cells in human glaucoma and in a rat model. Invest Ophthalmol Vis Sci 2006; 47(9): 3853-9
86. Attwell D, Buchan AM, Charpak S, Lauritzen M, Macvicar BA, Newman EA. Glial and neuronal control of brain blood flow. Nature 2010; 468(7321): 232-43
87. Toft-Kehler AK, Skytt DM, Poulsen KA, et al. Limited energy supply in Müller cells alters glutamate uptake. Neurochem Res 2014; 39(5): 941-9
88. Feilchenfeld Z, Yücel YH, Gupta N. Oxidative injury to blood vessels and glia of the pre-laminar optic nerve head in human glaucoma. Exp Eye Res 2008; 87(5): 409-14
89. Javadiyan S, Burdon KP, Whiting MJ, et al. Elevation of serum asymmetrical and symmetrical dimethylarginine in patients with advanced glaucoma. Invest Ophthalmol Vis Sci 2012; 53(4): 1923-7
90. Ko M-L, Peng P-H, Ma M-C, Ritch R, Chen C-F. Dynamic changes in reactive oxygen species and antioxidant levels in retinas in experimental glaucoma. Free Radic Biol Med 2005; 39(3): 365-73
91. Moreno MC, Campanelli J, Sande P, Sánez DA, Keller Sarmiento MI, Rosenstein RE. Retinal oxidative stress induced by high intraocular pressure. Free Radic Biol Med 2004; 37(6): 80312
92. Tezel G, Yang X, Cai J. Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci 2005; 46(9): 3177-87
93. Birich TV, Birich TA, Marchenko LN, Remizonova DN, Fedylov AS. Vitamin E in the complex treatment of patients with primary glaucoma. Vestn Oftalmol 1986; 102(2): 10-3
94. Cellini M, Caramazza N, Mangiafico P, Possati GL, Caramazza R. Fatty acid use in glaucomatous optic neuropathy treatment. Acta Ophthalmol Scand 1998; 227: 41-2
95. Hsu K-H, Lazon de la Jara P., Ariyavidana A., et al. Release of betaine and dexpanthenol from vitamin E modified silicone-hydrogel contact lenses. Curr Eye Res 2014; 15: 1-7
96. Peng C-C, Ben-Shlomo A, Mackay EO, Plummer CE, Chauhan A. Drug delivery by contact lens in spontaneously glaucomatous dogs. Curr Eye Res 2012; 37(3): 204-11
97. Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J. Protection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalide. Biochem Pharmacol 1995; 50(7): 991-9
98. Abdel-Kader R, Hauptmann S, Keil U, et al. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res 2007; 56(6): 493-502
99. Chandrasekaran K, Mehrabian Z, Spinnewyn B, Chinopoulos C, Drieu K, Fiskum G. Bilobalide, a component of the Ginkgo biloba extract (EGb 761), protects against neuronal death in global brain ischemia and in glutamate-induced excitotoxicity. Cell Mol Biol (Noisy-le-grand) 2002; 48(6): 663-9
100. Eckert A, Keil U, Scherping I, Hauptmann S, Müller WE. Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann N Y Acad Sci 2005; 1056: 474-85
101. Cybulska-Heinrich AK, Mozaffarieh M, Flammer J. Ginkgo biloba: an adjuvant therapy for progressive normal and high tension glaucoma. Mol Vis 2012; 18: 390-402
102. Abu-Amero KK, Morales J, Bosley TM. Mitochondrial abnormalities in patients with primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2006; 47(6): 2533-41
103. Chrysostomou V, Rezania F, Trounce IA, Crowston JG. Oxidative stress and mitochondrial dysfunction in glaucoma. Curr Opin Pharmacol 2013; 13(1): 12-5
104. Lee S, Sheck L, Crowston JG, et al. Impaired complex-I-linked respiration and ATP synthesis in primary open-angle glaucoma patient lymphoblasts. Invest Ophthalmol Vis Sci 2012; 53(4): 2431-7
105. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies-disease mechanisms and therapeutic strategies. Prog Retinal Eye Res 2011; 30(2): 81-114
106. Nucci C, Tartaglione R, Cerulli A, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol 2007; 82: 397-406
107. Russo R, Cavaliere F, Rombolà L, et al. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection. Prog Brain Res 2008; 173: 575-82
108. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, Hara H. Coenzyme Q10 protects retinal cells against oxidative stress in vitro and in vivo. Brain Res 2008; 1226: 226-33
109. McKinnon SJ. The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. Invest Ophthalmol Vis Sci 2012; 53(5): 2485-7
110. Agarwal R, Agarwal P. Glaucomatous neurodegeneration: an eye on tumor necrosis factor-alpha. Indian J Ophthalmol 2012; 60(4): 255-61
111. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008; 173: 409-21
112. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002; 22(7): RC216
113. Lebrun-Julien F, Bertrand MJ, De Backer O, et al. ProNGF induces TNFalpha-dependent death of retinal ganglion cells through a p75NTR non-cell-autonomous signaling pathway. Proc Natl Acad Sci USA 2010; 107(8): 3817-22
114. Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006; 26(49): 12633-41
115. Tezel G, Yang X, Yang J, Wax MB. Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res 2004; 996(2): 202-12
116. Ahmed Z, Aslam M, Lorber B, Suggate EL, Berry M, Logan A. Optic nerve and vitreal inflammation are both RGC neuroprotective but only the latter is RGC axogenic. Neurobiol Dis 2010; 37(2): 441-54
117. Roh M, Zhang Y, Murakami Y, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS ONE 2012; 7(7): e40065
118. Dong C-J, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49(10): 4515-22
119. Pan Y-Z, Li D-P, Pan H-L. Inhibition of glutamatergic synaptic input to spinal lamina II(o) neurons by presynaptic alpha(2)-adrenergic receptors. J Neurophysiol 2002; 87(4): 1938-47
120. Hong S, Park K, Kim CY, Seong GJ. Agmatine inhibits hypoxia- induced TNF-alpha release from cultured retinal ganglion cells. Biocell 2008; 32(2): 201-5
121. Hong S, Kim CY, Lee WS, Shim J, Yeom HY, Seong GJ. Ocular hypotensive effects of topically administered agmatine in a chronic ocular hypertensive rat model. Exp Eye Res 2010; 90(1): 97-103
122. García E, Silva-García R, Mestre H, et al. Immunization with A91 peptide or copolymer-1 reduces the production of nitric oxide and inducible nitric oxide synthase gene expression after spinal cord injury. J Neurosci Res 2012; 90(3): 656-63
123. Schori H, Kipnis J, Yoles E, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001; 98(6): 3398-403
124. Nilforushan N. Neuroprotection in glaucoma. J Ophthalmic Vis Res 2012; 7(1): 91-3
125. Brust A-K, Ulbrich HK, Seigel GM, Pfeiffer N, Grus FH. Effects of cyclooxygenase inhibitors on apoptotic neuroretinal cells. Biomark Insights 2008; 3: 387-402
126. Collaço-Moraes Y, Aspey B, Harrison M, de Belleroche J. Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia. J Cereb Blood Flow Metab 1996; 16(6): 1366-72
127. Sakai Y, Tanaka T, Seki M, et al. Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice. Neurosci Res 2009; 65(4): 319-25
128. Kawasaki A, Han M-H, Wei J-Y, Hirata K, Otori Y, Barnstable CJ. Protective effect of arachidonic acid on glutamate neurotoxicity in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2002; 43(6): 1835-42
129. Kolko M, DeCoster MA, de Turco EB, Bazan NG. Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. J Biol Chem 1996; 271(51): 32722-8
130. Helin M, Rönkkö S, Puustjärvi T, Teräsvirta M, Uusitalo H. Phospholipases A2 in normal human conjunctiva and from patients with primary open-angle glaucoma and exfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol 2008; 246(5): 739-46
131. Rönkkö S, Rekonen P, Kaarniranta K, Puustjärvi T, Teräsvirta M, Uusitalo H. Phospholipase A2 in chamber angle of normal eyes and patients with primary open angle glaucoma and exfoliation glaucoma. Mol Vis 2007; 13: 408-17
132. Yagami T, Ueda K, Sakaeda T, et al. Effects of an endothelin B receptor agonist on secretory phospholipase A2-IIA-induced apoptosis in cortical neurons. Neuropharmacology 2005; 48(2): 291-300
133. Yagami T, Ueda K, Asakura K, et al. Human group IIA secretory phospholipase A2 induces neuronal cell death via apoptosis. Mol Pharmacol 2002; 61(1): 114-26
134. 2+ channels in cultured rat cortical neurons. J Neurochem 2003; 85(3): 749-58
135. Doh SH, Kim JH, Lee KM, Park HY, Park CK. Retinal ganglion cell death induced by endoplasmic reticulum stress in a chronic glaucoma model. Brain Res 2010; 1308: 158-66
136. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci USA 2007; 104(33): 13444-9
137. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002; 43(4): 1077-87
138. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 2005; 49(2): 106-8
139. Tezel G, Hernandez R, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol 2000; 118(4): 511-8
140. Qing G, Duan X, Jiang Y. Heat shock protein 72 protects retinal ganglion cells in rat model of acute glaucoma. Yan Ke Xue Bao 2005; 21(3): 163-8
141. Ishii Y, Kwong JMK, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003; 44(5): 1982-92
142. Uchida S, Fujiki M, Nagai Y, Abe T, Kobayashi H. Geranylgeranylacetone, a noninvasive heat shock protein inducer, induces protein kinase C and leads to neuroprotection against cerebral infarction in rats. Neurosci Lett 2006; 396(3): 220-4
143. Bringmann A, Grosche A, Pannicke T, Reichenbach A. GABA and glutamate uptake and metabolism in retinal glial (Müller) cells. Front Endocrinol (Lausanne) 2013; 2013; 4: 48
144. Junier MP. What role(s) for TGFalpha in the central nervous system? Prog Neurobiol 2000; 62(5): 443-73
145. Liu X, Clark AF, Wordinger RJ. Expression of ciliary neurotrophic factor (CNTF) and its tripartite receptor complex by cells of the human optic nerve head. Mol Vis 2007; 13: 758-63
146. Gris P, Tighe A, Levin D, Sharma R, Brown A. Transcriptional regulation of scar gene expression in primary astrocytes. Glia 2007; 55(11): 1145-55
147. Leibinger M, Müller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D. Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J Neurosci 2009; 29(45): 14334-41
148. Rose K, Litterscheid S, Klumpp S, Krieglstein J. Fibroblast growth factor 2 requires complex formation with ATP for neuroprotective activity. Neuroscience 2009; 164(4): 1695-700
149. Prokai-Tatrai K., Xin H., Nguyen V., et al. 17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma. Mol Pharm 2013; 10(8): 3253-61
150. Marcus MW, Müskens RPHM, Ramdas WD, et al. Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS ONE 2012; 7(1): e29724
151. Stein JD, Newman-Casey PA, Talwar N, Nan B, Richards JE, Musch DC. The relationship between statin use and open-angle glaucoma. Ophthalmology 2012; 119(10): 2074-81
152. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007; 48(3): 1212-8
153. Tsai JC, Wu L, Worgul B, Forbes M, Cao J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res 2005; 30(11): 1025-31
154. Bertrand J, Winton MJ, Rodriguez-Hernandez N, Campenot RB, McKerracher L. Application of Rho antagonist to neuronal cell bodies promotes neurite growth in compartmented cultures and regeneration of retinal ganglion cell axons in the optic nerve of adult rats. J Neurosci 2005; 25(5): 1113-21
155. Lehmann M, Fournier A, Selles-Navarro I, et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999; 19(17): 7537-47
156. Sengottuvel V, Leibinger M, Pfreimer M, Andreadaki A, Fischer D. Taxol facilitates axon regeneration in the mature CNS. J Neurosci 2011; 31(7): 2688-99
157. Leibinger M, Andreadaki A, Fischer D. Role of mTOR in neuroprotection and axon regeneration after inflammatory stimulation. Neurobiol Dis 2012; 46(2): 314-24
158. Jo SA, Wang E, Benowitz LI. Ciliary neurotrophic factor is an axogenesis factor for retinal ganglion cells. Neuroscience 1999; 89(2): 579-91
159. Fischer D, He Z, Benowitz LI. Counteracting the Nogo receptor enhances optic nerve regeneration if retinal ganglion cells are in an active growth state. J Neurosci 2004; 24(7): 1646-51
160. Su Y, Wang F, Teng Y, Zhao S-G, Cui H, Pan S-H. Axonal regeneration of optic nerve after crush in Nogo66 receptor knockout mice. Neurosci Lett 2009; 460(3): 223-6
161. Fischer D, Pavlidis M, Thanos S. Cataractogenic lens injury prevents traumatic ganglion cell death and promotes axonal regeneration both in vivo and in culture. Invest Ophthalmol Vis Sci 2000; 41(12): 3943-54
162. Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci USA 1994; 91(5): 1632-6
163. Johnson TV, Bull ND, Martin KR. Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res 2011; 93(2): 196-203
164. Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci 2010; 51(4): 2051-9
165. Li N, Li X-R, Yuan J-Q. Effects of bone-marrow mesenchymal stem cells transplanted into vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp Ophthalmol 2009; 247(4): 503-14
166. Ng TK, Fortino VR, Pelaez D, Cheung HS. Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells 2014; 6(2): 111-9
167. Yu S, Tanabe T, Dezawa M, Ishikawa H, Yoshimura N. Effects of bone marrow stromal cell injection in an experimental glaucoma model. Biochem Biophys Res Commun 2006; 344(4): 1071-9
168. Zwart I, Hill AJ, Al-Allaf F, et al. Umbilical cord blood mesenchymal stromal cells are neuroprotective and promote regeneration in a rat optic tract model. Exp Neurol 2009; 216(2): 439-48